BAO PHARMA-B Surges Over 7% in Morning Trading as KJ103 Injection Advances to Priority Review

Stock News05-13

BAO PHARMA-B (02659) rose more than 7% in morning trading. As of press time, the stock was up 6.99% to HK$29.4, with a turnover of HK$86.0639 million. On the news front, on May 12, the CDE website indicated that BAO PHARMA's KJ103 injection is proposed to be included in the priority review process. It is intended for desensitization therapy in highly sensitized kidney transplant patients, effectively clearing pre-existing HLA antibodies to prevent hyperacute rejection. According to reports, KJ103 is a first-in-class, low-immunogenicity recombinant immunoglobulin G (IgG) degrading enzyme for the treatment of various immune diseases mediated by pathological IgG antibodies. The product works by specifically cleaving and degrading pathological IgG antibodies in the bloodstream, inhibiting immune response activation, and providing a targeted, rapid new treatment option for antibody-mediated autoimmune diseases.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1182859003?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-13 10:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1182859003","market":"other","top_or_hot":-1,"title":"BAO PHARMA-B Surges Over 7% in Morning Trading as KJ103 Injection Advances to Priority Review","media":"Stock News","content":"<p>BAO PHARMA-B (02659) rose more than 7% in morning trading. As of press time, the stock was up 6.99% to HK$29.4, with a turnover of HK$86.0639 million. On the news front, on May 12, the CDE website indicated that BAO PHARMA's KJ103 injection is proposed to be included in the priority review process. It is intended for desensitization therapy in highly sensitized kidney transplant patients, effectively clearing pre-existing HLA antibodies to prevent hyperacute rejection. According to reports, KJ103 is a first-in-class, low-immunogenicity recombinant immunoglobulin G (IgG) degrading enzyme for the treatment of various immune diseases mediated by pathological IgG antibodies. The product works by specifically cleaving and degrading pathological IgG antibodies in the bloodstream, inhibiting immune response activation, and providing a targeted, rapid new treatment option for antibody-mediated autoimmune diseases.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BAO PHARMA-B Surges Over 7% in Morning Trading as KJ103 Injection Advances to Priority Review</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBAO PHARMA-B Surges Over 7% in Morning Trading as KJ103 Injection Advances to Priority Review\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-05-13 10:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BAO PHARMA-B (02659) rose more than 7% in morning trading. As of press time, the stock was up 6.99% to HK$29.4, with a turnover of HK$86.0639 million. On the news front, on May 12, the CDE website indicated that BAO PHARMA's KJ103 injection is proposed to be included in the priority review process. It is intended for desensitization therapy in highly sensitized kidney transplant patients, effectively clearing pre-existing HLA antibodies to prevent hyperacute rejection. According to reports, KJ103 is a first-in-class, low-immunogenicity recombinant immunoglobulin G (IgG) degrading enzyme for the treatment of various immune diseases mediated by pathological IgG antibodies. The product works by specifically cleaving and degrading pathological IgG antibodies in the bloodstream, inhibiting immune response activation, and providing a targeted, rapid new treatment option for antibody-mediated autoimmune diseases.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"","article_id":"1182859003","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1182859003","pubTimestamp":1778638527,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"BAO PHARMA-B (02659) rose more than 7% in morning trading. As of press time, the stock was up 6.99% to HK$29.4, with a turnover of HK$86.0639 million. On the news front, on May 12, the CDE website...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK1161":"生物科技","VXUS":"国际股票ETF-Vanguard","02659":"宝济药业-B","BK4588":"碎股"},"translate_title":"宝药业-B早盘大涨超7%，KJ103注射液晋级优先审评","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02659":1,"VXUS":1},"content_text":"BAO PHARMA-B (02659) rose more than 7% in morning trading. As of press time, the stock was up 6.99% to HK$29.4, with a turnover of HK$86.0639 million. On the news front, on May 12, the CDE website indicated that BAO PHARMA's KJ103 injection is proposed to be included in the priority review process. It is intended for desensitization therapy in highly sensitized kidney transplant patients, effectively clearing pre-existing HLA antibodies to prevent hyperacute rejection. According to reports, KJ103 is a first-in-class, low-immunogenicity recombinant immunoglobulin G (IgG) degrading enzyme for the treatment of various immune diseases mediated by pathological IgG antibodies. The product works by specifically cleaving and degrading pathological IgG antibodies in the bloodstream, inhibiting immune response activation, and providing a targeted, rapid new treatment option for antibody-mediated autoimmune diseases.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1182859003","isCrawlerRequest":true}